A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Advanced breast cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 16 Feb 2018 This trial has been completed in Spain, according to European Clinical Trials Database
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2017 Status changed from active, no longer recruiting to recruiting.